Pfizer posts Phase 3 data for Lyme vaccine candidate LB6V at IDWeek 2026

Pfizer flagged Phase 3 results for its LB6V Lyme disease vaccine candidate, with IDWeek 2026 presentations scheduled Oct. 22. The readout supported the shot’s ability to protect against Lyme disease, strengthening its case as a potential new commercial vaccine entrant. Regulatory momentum advanced in Europe, with the EMA starting its review of the marketing application in August 2026. Separate IDWeek 2026 presentations will cover Phase 2 data for a 25-valent pediatric pneumococcal candidate, with results previously announced in May 2026. Pfizer also highlighted Phase 3 findings for an LP.8.1-adapted Comirnaty formulation in at-risk children, supporting its updated COVID-19 franchise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via (Ref. ID: 20261014474581) on October 14, 2026, and is solely responsible for the information contained therein. (C) Co